Market Overview

Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings

Share:
Related NAVB
Benzinga's M&A Chatter for Tuesday September 6, 2016
Mid-Afternoon Market Update: Gold Futures Up 2%; CoLucid Shares Climb After Migraine Drug Achieves Primary And Key Secondary Endpoints
Where Does Navidea Go From Here? (Seeking Alpha)

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced that data from its Lymphoseek^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

Posted-In: News

 

Related Articles (NAVB)

View Comments and Join the Discussion!